HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (19) Citing Articles via Google Scholar Google Scholar Articles by Walmrath, D. Articles by Seeger, W. Search for Related Content PubMed PubMed Citation Articles by Walmrath, D. Articles by Seeger, W.

Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics

¹ Dept of Internal Medicine II, ³ Dept of Anesthesiology and Intensive Care Medicine, Justus-Liebig-University, Giessen, Germany; ² Dept of Anesthesiology and Intensive Care Medicine, Klinikum Rudolf Virchow, Berlin, Germany; ⁴ Dept of Trauma Surgery, University of Essen, Germany; ⁵ Dept of Anesthesiology, Albert-Ludwigs-University, Freiburg, Germany

CORRESPONDENCE: W. Seeger, Dept of Internal Medicine, Justus-Liebig University Giessen, Klinikstrasse 36, D-35392, Giessen, Germany. Fax: 49 6419942359. E-mail: Werner.Seeger@innere.med.uni-giessen.de

Keywords: acute respiratory distress syndrome, gas exchange, septic shock, surfactant administration

Received: May 9, 2001
Accepted January 9, 2002

This study was supported by the Deutsche Forschungsgemeinschaft.

The aim of the present study was to investigate the feasibility and efficacy of bronchoscopic surfactant administration in a noncontrolled multicentre study in five university centres.

A total number of 27 patients, suffering from severe acute respiratory distress syndrome (mean±sem lung injury score: 3.15±0.06) and septic shock (Acute Physiology and Chronic Health Evaluation (APACHE) II score at study entry 33.2±1.3, lactate 4.3±0.6 mmol·L^–1) were studied. The patients were ventilated with a mean tidal volume of 11.0±0.5 mL·kg^–1 body weight (bw), either volume or pressure controlled, with 16.3±2.8 cmH₂O positive end-expiratory pressure, for an average of 3.5±0.3 days at study entry. A natural bovine surfactant extract (300 mg·kg^–1 bw Alveofact®; mean total volume 378 mL) was delivered in divided doses to each segment of the lungs via flexible bronchoscope within 45 min.

No untoward effects on gas exchange, lung mechanics and haemodynamics were noted during the procedure of surfactant administration. Within 12 h the oxygen tension in arterial blood/inspiratory oxygen fraction increased from a mean of 109±8 mmHg to 210±20 mmHg (p<0.001). In seven patients, in whom gas exchange again deteriorated with further progression of the disease, a second surfactant dose of 200 mg·kg^–1 was administered 18–24 h after the first application, again improving arterial oxygenation. A total of 15 patients survived the 28-day study period (mortality rate 44.4%, compared to a calculated risk of death for the given APACHE II scores of 74.0±3.5%), with all causes of death being nonrespiratory. The bronchoscopic application of a high dose of natural surfactant in patients with severe acute respiratory distress syndrome and septic shock is both feasible and safe, resulting in a pronounced improvement in gas exchange.

This article has been cited by other articles:

				P. Markart, C. Ruppert, M. Wygrecka, T. Colaris, B. Dahal, D. Walmrath, H. Harbach, J. Wilhelm, W. Seeger, R. Schmidt, et al. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids Thorax, July 1, 2007; 62(7): 588 - 594. [Abstract] [Full Text] [PDF]

				M. Cepkova and M. A. Matthay Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med, May 1, 2006; 21(3): 119 - 143. [Abstract] [PDF]

				B. S. Burleson and E. D. Maki Acute Respiratory Distress Syndrome Journal of Pharmacy Practice, April 1, 2005; 18(2): 118 - 131. [Abstract] [PDF]

				A. Gunther, M. Balser, R. Schmidt, P. Markart, A. Olk, J. Borgermann, F. H. Splittgerber, W. Seeger, and I. Friedrich Surfactant abnormalities after single lung transplantation in dogs: Impact of bronchoscopic surfactant administration J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 344 - 354. [Abstract] [Full Text] [PDF]

				F. S. Cole Surfactant protein B: unambiguously necessary for adult pulmonary function Am J Physiol Lung Cell Mol Physiol, September 1, 2003; 285(3): L540 - L542. [Full Text] [PDF]

				R. G. Spragg, J. F. Lewis, W. Wurst, D. Hafner, R. P. Baughman, M. D. Wewers, and J. J. Marsh Treatment of Acute Respiratory Distress Syndrome with Recombinant Surfactant Protein C Surfactant Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1562 - 1566. [Abstract] [Full Text] [PDF]

				A. Anzueto Exogenous surfactant in acute respiratory distress syndrome: more is better Eur. Respir. J., May 1, 2002; 19(5): 787 - 789. [Full Text] [PDF]

				A. Gunther, R. Schmidt, J. Harodt, T. Schmehl, D. Walmrath, C. Ruppert, F. Grimminger, and W. Seeger Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties Eur. Respir. J., May 1, 2002; 19(5): 797 - 804. [Abstract] [Full Text] [PDF]